CIDP患者を対象としたリリプルバートの長期安全性および有効性試験
基本情報
- NCT ID
- NCT06859099
- ステータス
- 招待制
- 試験のフェーズ
- 第3相
- 試験タイプ
- 介入
- 目標被験者数
- 300
- 治験依頼者名
- Sanofi
概要
This study is a Phase 3 extension, global, multicenter open-label study. The purpose of this study is to evaluate long-term safety and efficacy of riliprubart in adult participants with chronic inflammatory demyelinating polyneuropathy (CIDP) who have completed Part B in 1 of 3 parent studies (PDY16744, EFC17236, or EFC18156) and wish to continue treatment with riliprubart. Up to approximately 300 participants will be enrolled to continue receiving treatment with riliprubart. The duration of participation for each participant will be up to approximately 4 years, including posttreatment follow-up. The treatment duration will be up to approximately 3 years. A participant who discontinues riliprubart treatment at any time during the study will be followed for safety for a minimum of 55 weeks after the last dose of riliprubart received.